On March 13, 2025, Xencor, Inc. announced the appointment of Todd Simpson to its board of directors. Mr. Simpson brings over 40 years of experience in chief financial officer (CFO) roles at multiple biopharmaceutical companies.
Most recently, Mr. Simpson served as CFO at Seagen Inc. through its acquisition in 2023. His extensive background in public accounting and biopharmaceutical finance is expected to contribute to Xencor's strategic direction.
This appointment strengthens Xencor's board with seasoned financial expertise, which is crucial for a clinical-stage company managing significant R&D investments and aiming for long-term growth.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.